Poltreg S.A. (WSE: PTG)

Poland flag Poland · Delayed Price · Currency is PLN
41.70
+4.30 (11.50%)
Jan 20, 2025, 12:53 PM CET
-13.66%
Market Cap 180.01M
Revenue (ttm) 550.00K
Net Income (ttm) -18.37M
Shares Out 4.66M
EPS (ttm) -3.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,285
Average Volume 908
Open 40.10
Previous Close 37.40
Day's Range 39.10 - 41.70
52-Week Range 36.60 - 57.80
Beta 0.98
RSI 47.97
Earnings Date Apr 17, 2025

About Poltreg

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases. It engages in the research and development of therapies for the treatment of type 1 diabetes in children, and multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 23
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PTG
Full Company Profile

Financial Performance

In 2023, Poltreg's revenue was 1.40 million, an increase of 40.04% compared to the previous year's 999,000. Losses were -13.55 million, 588.9% more than in 2022.

Financial Statements

News

There is no news available yet.